#ACTIV4a - Twitter Hashtag

about 3 years ago

#ACTIV4a LBCT #ISTH2023 & simpub in @CircAHA! Major multicenter effort led by @scottdsolomon testing a fundamental question in pathobiology of #COVID19 #Crizanlizumab (P-selectin inhibitor) did not improve organ-support free days in patients w #COVID19 https://t.co/QKzqaOrlXW

mvaduganathan's tweet photo. #ACTIV4a LBCT #ISTH2023 & simpub in @CircAHA!

Major multicenter effort led by @scottdsolomon testing a fundamental question in pathobiology of #COVID19

#Crizanlizumab (P-selectin inhibitor) did not improve organ-support free days in patients w #COVID19

https://t.co/QKzqaOrlXW https://t.co/Bumowtpz9Z

1

50

18

0

21K

Behnood Bikdeli @bbikdeli

about 3 years ago

#ACTIV4a results for crizanlizumab for pts w #COVID19 by Dr. Lowenstein @HopkinsMedicine @isth #ISTH 2023, sim pub in @CircAHA. Bottomline: It doesn’t work. ?if harm. Editorial by Dr. Eikelboom & I to come soon. #pselectin https://t.co/7zh2gYmY12

bbikdeli's tweet photo. #ACTIV4a results for crizanlizumab for pts w #COVID19 by Dr. Lowenstein @HopkinsMedicine @isth #ISTH 2023, sim pub in @CircAHA. Bottomline: It doesn’t work. ?if harm. Editorial by Dr. Eikelboom & I to come soon. #pselectin

https://t.co/7zh2gYmY12 https://t.co/ezXOJezmsK

0

10

0

590

Henry Han

@HanCardiomd

over 4 years ago

Let’s see how #flozinators will play in #ACTIV4a Two specific agents to be added as arms, include the P-selectin inhibitor, Crizanlizumab as well as #SGLT2i SGLT2 inhibitors have been shown to decrease capillary leak and may promote vascular integrity in COVID-19 @ACTIV4a

HanCardiomd's tweet photo. Let’s see how #flozinators will play in #ACTIV4a

Two specific agents to be added as arms, include the P-selectin inhibitor, Crizanlizumab as well as #SGLT2i

SGLT2 inhibitors have been shown to decrease capillary leak and may promote vascular integrity in COVID-19
@ACTIV4a https://t.co/tx9VHbHoX3

Muthu Vaduganathan @mvaduganathan

over 4 years ago

#ACTIV4a Platform RCT to now include #SGLT2i arm in hospitalized pts with moderate-to-severe #COVID19. Enrollment underway @scottdsolomon @MkosiborodMD @ankeetbhatt Together with #RECOVERY & #DARE19, will form robust evidence base for #SGLT2i in #COVID19 https://t.co/VQ7L6tIFF7

mvaduganathan's tweet photo. #ACTIV4a Platform RCT to now include #SGLT2i arm in hospitalized pts with moderate-to-severe #COVID19. Enrollment underway @scottdsolomon @MkosiborodMD @ankeetbhatt

Together with #RECOVERY & #DARE19, will form robust evidence base for #SGLT2i in #COVID19

https://t.co/VQ7L6tIFF7 https://t.co/fSEDNNtlYs

0

45

11

1

0

6

0

Muthu Vaduganathan @mvaduganathan

over 4 years ago

#ACTIV4a Platform RCT to now include #SGLT2i arm in hospitalized pts with moderate-to-severe #COVID19. Enrollment underway @scottdsolomon @MkosiborodMD @ankeetbhatt Together with #RECOVERY & #DARE19, will form robust evidence base for #SGLT2i in #COVID19 https://t.co/VQ7L6tIFF7

0

45

11

1

0

Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦

@DrMarthaGulati

over 4 years ago

#AHA21 #LBCT P2y12 Inhibitors in Noncritically Ill Hospitalized Pts With #Covid_19 #ACTIV4A 🩸thrombosis/inflam in #COVID 🩸RCT of P2Yy12, non-critical pt: 562 pts 🩸Stopped for futility; 40% women; Ticag used in 63% 🩸 No benefit of P2Yy12 in non-critical pts @AHAMeetings

DrMarthaGulati's tweet photo. #AHA21 #LBCT
P2y12 Inhibitors in Noncritically Ill Hospitalized Pts With #Covid_19 #ACTIV4A
🩸thrombosis/inflam in #COVID
🩸RCT of P2Yy12, non-critical pt: 562 pts
🩸Stopped for futility; 40% women; Ticag used in 63%
🩸 No benefit of P2Yy12 in non-critical pts
@AHAMeetings https://t.co/kScFoGNOMW

1

24

5

0

Suchita Shah Sata, MD @SuchitaSata

almost 5 years ago

Way to go @Duke_GIM! @DukeHospital #COVID researchers, including hospitalists leading efforts in #ACTIV4a trial and so many other trials to help our patients, with 2 pubs in @NEJM

0

8

0

Ryan Kerzner 🇨🇦 @Pharmacist_MTL

over 5 years ago

The first pre-print has arrived! Therapeutic Anticoagulation in Critically Ill Patients with Covid-19-Preliminary Report | medRxiv #ATTACC #REMAPCAP #ACTIV4a https://t.co/J546Fy2JF3

0

2

1

0

Dominik Scharpf @dscharpfMD

over 5 years ago

#intensivmedizin #COVID19 Interimsauswertung der Multiplatform RCT (#ATTACC, #REMAPCAP, #ACTIV4a) nun veröffentlicht. Bisher KEINE Reduktion der Gesamtmortalität trotz deutlich weniger thrombembolischer Events. Warten wir die weiteren Ergebnisse ab. https://t.co/jUzTjbMdG8

0

1

0

Servicio Neumología HRyC @HrcServicio

over 5 years ago

Los Servicios de Neumología y Neurología del HRyC trabajan para generar la mejor evidencia sobre el tratamiento antitrombótico de los pacientes con COVID-19: https://t.co/CIQCc3QW27 #INSPIRATION #ACTIV4a @josendon @MasjuanJaime

0

15

7

3

0

Pablo Guisado Vasco @PabloGVasco

over 5 years ago

@remap_cap and #Activ4a stop enrolling patients in severe #COVID19 in ICU for futility. This research gives us an important messages: active search of DVT/PE if extreme (>20 upper limits) elevation of d- dimer 👏🏻👏🏻

manuel monreal @mmonrealriete

over 5 years ago

We used data from hospitalized patients with COVID-19 that were tested for PE or DVT because of raised D-dimer levels We aimed to identify patients at increased risk for VTE Here: https://t.co/xxHVhFmmUJ

mmonrealriete's tweet photo. We used data from hospitalized patients with COVID-19 that were tested for PE or DVT because of raised D-dimer levels

We aimed to identify patients at increased risk for VTE

Here: https://t.co/xxHVhFmmUJ https://t.co/cloBErHk8n

2

50

30

4

0

3

5

1

0

Pablo Guisado Vasco @PabloGVasco

over 5 years ago

#ACTIV4a study, full anti coagulation vs prophylactic in severe #COVID19 (ICU) cancel enrollment for futility. Messages: individual decisions and known diagnostic, d-dimer might related to inflammation @GteiSemi

David Steensma, MD @DavidSteensma

over 5 years ago

Wow - @nih_nhlbi-sponsored #ACTIV4a study of anticoagulation in severe #COVID19 (ICU) enrollment closed due to futility, and a concerning safety signal. When I think of all the severely ill patients treated with AC based on early non-randomized data/physiological rationale...😕

DavidSteensma's tweet photo. Wow - @nih_nhlbi-sponsored #ACTIV4a study of anticoagulation in severe #COVID19 (ICU) enrollment closed due to futility, and a concerning safety signal. When I think of all the severely ill patients treated with AC based on early non-randomized data/physiological rationale...😕 https://t.co/V0aX6qvnsj

10

135

61

25

0

2

1

0

David Steensma, MD @DavidSteensma

over 5 years ago

Wow - @nih_nhlbi-sponsored #ACTIV4a study of anticoagulation in severe #COVID19 (ICU) enrollment closed due to futility, and a concerning safety signal. When I think of all the severely ill patients treated with AC based on early non-randomized data/physiological rationale...😕

Ismail Raslan @itraslan

over 5 years ago

@DavidSteensma @Bloodman

2

21

11

4

0

10

135

61

25

0

Top Tweets for #ACTIV4a

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users